Can you take Tick-borne encephalitis (inactivated) vaccine with Vivimusta?

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Adult and pediatric patients treated with bendamustine have experienced Infection, including pneumonia, sepsis, septic shock, and death. Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Therapy with bendamustine should be administered cautiously in patients with compromised bone marrow reserve. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently.

The bendamustine in Vivimusta has a moderate potential interaction with Bone Marrow Depression/Low Blood Counts.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

Tick-borne encephalitis (inactivated) vaccine has a moderate potential interaction with Immunodeficiency.

Immune responses to tick-borne encephalitis vaccine may be reduced in some patients with altered immunocompetence.

The bendamustine in Vivimusta has a moderate potential interaction with Infection.

Infection, including pneumonia, sepsis, septic shock, hepatitis, and death has occurred in adult and pediatric patients treated with bendamustine. Care should be exercised when using this drug in patients whose bone marrow reserve may be severely depressed as these patients could be more susceptible to infections. Patients treated with this drug are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. It is recommended to advise patients with myelosuppression following treatment with this agent to contact a physician immediately if they have symptoms or signs of infection. Before starting treatment, patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation risks.

The bendamustine in Vivimusta has a major potential interaction with Liver Disease.

Bendamustine injection should be used with caution in patients with hepatic impairment. Bendamustine injection should not be used in patients with moderate (AST or ALT 2.5 to 10 X ULN and total bilirubin 1.5 to 3 X ULN) or severe (total bilirubin greater than 3 X ULN) hepatic impairment.

The bendamustine in Vivimusta has a major potential interaction with Renal Dysfunction.

Bendamustine injection should be used with caution in patients with mild or moderate renal impairment. Bendamustine injection should not be used in patients with CrCL < 40 mL/min.